脑膜瘤的分子与转化研究进展
脑膜瘤是最常见的原发性颅内肿瘤,现行世界卫生组织(WHO)分类基于组织病理学特征,但新兴分子数据表明基因组与表观基因组因素对肿瘤临床行为具有重要性。本文综述了可揭示脑膜瘤行为并已具备临床试验研究应用条件的最新分子改变知识,并概述了现有临床前模型格局。
要点
- 脑膜瘤是最常见的原发性颅内肿瘤,当前WHO分类基于组织病理学特征。
- 基因组与表观基因组因素对脑膜瘤临床行为具有重要性。
- 现有临床前模型格局已被综述,亟需能忠实再现脑膜瘤的动物模型。
核心结论
- 脑膜瘤分子与基因组研究领域已处于将分子知识用于细化分类并引入可指导预测和治疗的分子算法的阶段。
研究设计与样本
- 综述,总结脑膜瘤分子改变的最新知识及现有临床前模型格局。
主要发现
- 新兴分子数据表明基因组和表观基因组因素对脑膜瘤临床行为具有重要性。
- 过去十年分子与基因组技术的进步促使对脑膜瘤基因组和表观基因组格局的研究兴趣激增。
临床怎么用
- 对有症状脑膜瘤的治疗选择限于尽可能的手术切除,以及对具有令人担忧的组织病理学特征或复发疾病的肿瘤进行辅助放疗。
- 目前尚无替代辅助治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.
引用
- Suppiah S, Nassiri F, Bi WL, et al. Molecular and translational advances in meningiomas. Neuro Oncol. 2019. PMID: 30649490. doi:10.1093/neuonc/noy178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。